Cite
Ozeki M, Asada R, Saito AM, et al. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA). Regen Ther. 2019;10:84-91doi: 10.1016/j.reth.2018.12.001.
Ozeki, M., Asada, R., Saito, A. M., Hashimoto, H., Fujimura, T., Kuroda, T., Ueno, S., Watanabe, S., Nosaka, S., Miyasaka, M., Umezawa, A., Matsuoka, K., Maekawa, T., Yamada, Y., Fujino, A., Hirakawa, S., Furukawa, T., Tajiri, T., Kinoshita, Y., Souzaki, R., & Fukao, T. (2019). Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA). Regenerative therapy, 1084-91. https://doi.org/10.1016/j.reth.2018.12.001
Ozeki, Michio, et al. "Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)." Regenerative therapy vol. 10 (2019): 84-91. doi: https://doi.org/10.1016/j.reth.2018.12.001
Ozeki M, Asada R, Saito AM, Hashimoto H, Fujimura T, Kuroda T, Ueno S, Watanabe S, Nosaka S, Miyasaka M, Umezawa A, Matsuoka K, Maekawa T, Yamada Y, Fujino A, Hirakawa S, Furukawa T, Tajiri T, Kinoshita Y, Souzaki R, Fukao T. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA). Regen Ther. 2019 Jan 14;10:84-91. doi: 10.1016/j.reth.2018.12.001. eCollection 2019 Jun. PMID: 30705924; PMCID: PMC6348766.
Copy
Download .nbib